Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review

Table 2 Overall results of the pairwise correlations

Endpoint	bALP		NTx	CTx		PINP
Endpoint	P	r	P	r	P	r	P	r
Baseline
Vertebral fractures	0.0001	0.8	0.3	0.3	0.6	0.1	0.4	0.2
Non-vertebral fractures	0.01	0.7	0.1	0.9	0.8	−0.1	0.3	0.2
BMD	0.01	−0.8	0.5	0.4	0.1	0.5	0.008	−0.4
BMI	0.9	0.0	0.09	−0.4	0.4	−0.3	0.2	−0.2
BMD spine	0.2	−0.3	0.6	0.2	0.04	−0.3	0.5	−0.1
BMD hip	0.04	−0.5	0.9	−0.1	0.01	0.5	0.06	0.4
BMD femur	0.003	−0.9	0.2	−0.5	0.0007	0.6	0.2	0.4
T score spine	0.4	−0.3	0.03	−0.7	0.5	−0.1	0.6	0.1
T score femur	0.07	0.5	0.08	−0.8	0.09	0.3	0.5	0.1
T score hip	0.1	1.0	0.04	−0.7	0.3	0.2	0.8	0.0
Follow-up
BMD spine	0.9	0.0	0.4	0.3	0.4	0.1	0.3	0.2
BMD hip	0.2	0.3	0.9	0.1	0.3	0.2	0.3	0.2
BMD femur	0.3	0.3	0.9	0.0	0.3	0.4	0.3	0.3
Body height	1.00	−1.0	0.1	−1.0	0.1	1.0	0.1	1.0
Non-vertebral fractures	0.3	−0.3	0.1	1.0	0.4	−0.2	0.7	−0.1
Vertebral fractures	0.5	−0.2	0.7	-0.2	0.3	−0.9	0.3	0.2
Hip fractures	1.00	1.0			1.0	−1.0
Femur fractures	0.1	−1.0			0.07	−0.7	0.1	−1.0
Adverse events	0.9	0.0	0.02	0.9	0.1	0.2	0.9	0.0
Serious adverse events	0.1	−1.0	0.9	0.2	0.1	0.3	0.5	0.2
Adverse events leading to discontinuation	0.1	0.6	0.3	−0.4	0.04	0.5	0.4	0.2
Gastrointestinal adverse events	0.3	−0.6	0.3	0.3	0.0001	0.7	0.02	0.6
Musculoskeletal adverse events	0.8	−0.1			0.04	0.4	0.4	0.2
Osteonecrosis					0.9	−0.1	0.4	−0.4
Mortality	1.00	1.0	0.93	0.1	0.04	0.6	0.1	0.5

ISSN: 1749-799X